Purpose To compare efficacy of pemetrexed versus pemetrexed plus carboplatin in
pretreated patients with advanced non–small-cell lung cancer (NSCLC). Patients and …

Background Subgroup analyses of randomized studies have consistently shown that
pemetrexed is exclusively effective in non-small-cell lung cancer (NSCLC) other than …

Purpose To compare single-agent pemetrexed (P) versus the combination of carboplatin
and pemetrexed (CP) in first-line therapy for patients with advanced non–small-cell lung …

Background Pemetrexed plus cisplatin was approved for first-line treatment of non–small-
cell lung cancer (NSCLC) in patients with nonsquamous histology after initiation of this …

To compare the efficacy and toxicities of pemetrexed plus platinum with other platinum
regimens in patients with previously untreated advanced non-small cell lung cancer …

Purpose: Platinum-based regimens represent the standard first-line treatment for non-small-
cell lung cancer (SNCLC). However, newer data have established a role for pemetrexed in …

7506 Background: No standard of care exists for patients with advanced NSCLC and PS 2
and clinical practice ranges from supportive care to combination chemotherapy. Methods: In …

Introduction: For patients with advanced NSCLC, treatment outcomes are still disappointing
and the search for new active and safe drugs is warranted. The chemotherapeutic agent …

Background The main objective of this study was to evaluate the safety of second-line
pemetrexed in Stage IIIB or IV NSCLC. Methods Overall, 95 patients received pemetrexed …

Purpose: To determine efficacy and toxicity of two pemetrexed-based regimens in
chemonaive patients with locally advanced or metastatic non–small cell lung cancer …